Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Proliferative Breast Disease 1Oligodendroglioma 1Neoplasm Metastasis 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Childhood Brain Neoplasm 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 7Radiotherapy 6Bevacizumab 5Magnetic Resonance Spectroscopy 3ribociclib 2olaparib 2fluorodopa F 18 2fluciclovine F-18 2atezolizumab 2abemaciclib 2Surgical Procedures, Operative 2Specimen Handling 2Radiation 2Ketoconazole 2Everolimus 2Disulfiram 2Carvedilol 2zimberelimab 1tinostamustine 1temsirolimus 1senicapoc 1sacituzumab govitecan 1posaconazole 1pitavastatin 1perampanel 1pamiparib 1palbociclib 1niraparib 1mycophenolic adenine dinucleotide 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Glioblastoma × Dynamic Contrast Enhanced Magnetic Resonance Imaging × Clear all
NCT01996527 2017-04-17

3T MRI Biomarkers of Glioma Treatment Response

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Terminated
7 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡